Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5)-Reference-Cited by-同舟云学术

Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5)

Published:2015-11 Issue:11 Volume:2 Page:e481-e491
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Mounier Morgane,Bossard Nadine,Remontet Laurent,Belot Aurélien,Minicozzi Pamela,De Angelis Roberta,Capocaccia Riccardo,Iwaz Jean,Monnereau Alain,Troussard Xavier,Sant Milena,Maynadié Marc,Giorgi Roch

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States;Sant;Eur J Cancer,2008

2. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues,2001

3. International Classification of Diseases for Oncology,2000

4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

5. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study;Salles;Blood,2008

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparities in mortality risk after diagnosis of hematological malignancies in 185 countries: A global data analysis;Cancer Letters;2024-07

2. Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis;Cancers;2023-09-02

3. Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi;Frontiers in Oncology;2023-03-10

4. Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group;Advances in Clinical and Experimental Medicine;2023-01-05

5. Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study;Transplantation and Cellular Therapy;2023-01